Elacestrant in ER+, HER2− Metastatic Breast Cancer with <i>ESR1</i> -Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
#4PRI RANKED
Most Cited Paper
in Estrogen and related hormone effects
18 Months Post-Publication
Class of 2026
“Elacestrant in ER+, HER2− Metastatic Breast Cancer with <i>ESR1</i> -Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
elacestrant · ESR1 mutation · ER+ HER2- metastatic breast cancer · CDK4/6 inhibitor · EMERALD trial · Progression-free survival · resistance · fulvestrant · aromatase inhibitor · ESR1 D538G mutation · ESR1 Y537S/N mutation · PIK3CA mutation · TP53 mutation · HER2-low · Bone metastases · liver and lung metastases · prior treatment duration · selective estrogen receptor degrader
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Estrogen and related hormone effects Papers, Class of 2026. https://pri.pepkio.com/top-papers/estrogen-and-related-hormone-effects/2026. Accessed 2026-07-31. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459